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Abstract
We study the impact of product margins on pharmaciesincentive to promote generics
instead of brand-names. First, we construct a theoretical model where pharmacies can
persuade patients with a brand-name prescription to purchase a generic version instead.
We show that pharmaciessubstitution incentives are determined by relative margins and
relative patient copayments. Second, we exploit a unique product level panel data set, which
contains information on sales and prices at both producer and retail level. In the empirical
analysis, we nd a strong relationship between the margins of brand-names and generics and
their market shares. This relationship is stronger for pharmaceuticals under reference pricing
rather than coinsurance. In terms of policy implications, our results suggest that pharmacy
incentives are crucial for promoting generic sales.
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1 Introduction
In this paper we study pharmaciesrole in promoting generic substitution and thus competition
between brand-names and generics. Most consumers enter the pharmacy with a prescription of a
brand-name product due to the tendency of physicians to prescribe brand-names rather than the
cheaper, but therapeutically equivalent, generic versions. Insurers (payers) therefore use various
instruments to increase competition and generic market shares in order to reduce pharmaceutical
expenditures. One important instrument is generic substitution regulation, which implies that
pharmacies can dispense a generic substitute to consumers with a brand-name prescription.
However, convincing consumers that a generic product is of the same quality (therapeutically
equivalent) as the brand-name product prescribed by the physician is likely to involve costly
promotional e¤ort by the pharmacies, so what are the incentives for pharmacies to engage in
generic substitution?
The obvious answer is the pharmaciesprotability of selling generics rather than brand-
names. We therefore study the role of pharmacies in promoting generic sales by analysing the
relationship between the margins that pharmacies obtain for brand-names and generics and their
respective market shares. We nd this issue interesting for several reasons. First, pharmaceutical
expenditures are growing in most Western countries, and the o¤-patent market is becoming
increasingly important as patents have expired for several blockbusters.1 Stimulating generic
competition is therefore seen as one of the most important instruments for regulators (payers)
to contain costs in this industry.
Second, our paper is, to the best of our knowledge, the rst to study the role of pharmacies
in promoting generic sales and the e¤ect of generic substitution regulation. There are several
papers on the physiciansprescription choice between brand-names and generics.2 There are also
1See, for instance, the reports by Pharma (2008) and EGA (2009). According to EGA (2009) about half of
the dispensed pharmaceuticals in the o¤-patent market segment in the European Union are generics, but there
are large variations across the member countries. In the US, however, the generic market share (in volume) in
this segment is about 90 percent. Thus, there should be great scope for regulatory policies to a¤ect the generic
sales and thus the pharmaceutical expenditures.
2Hellerstein (1998) uses US survey data and nds that physician characteristics (not patient characteristics)
explain why patients are prescribed a brand-name or a generic. Coscelli (2000) uses Italian microdata on pre-
scriptions and nds evidence for habit persistence for both physicians and patients. Finally, Lundin (2000) nds
that patients facing large copayments are less (more) likely to receive a brand-name (generic) prescription using
Swedish microdata.
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a few, recent papers on the physicianschoice of drug when they are allowed to dispense drugs
and can pocket the product margin.3 There is also a large literature on the impact of regulation
and copayment schemes on generic sales, where recent studies show that reference pricing, which
imposes extra copayments on patients that demand high-priced brand-names, tends to promote
generic sales and reduce prices and expenditures.4 None of these studies consider the role of
pharmacies in stimulating generic sales.
Finally, our study o¤ers insight into retailer incentives more broadly, as we study the promo-
tional incentives for steering consumers toward more protable products. The idea that retailers
can inuence consumerspurchase choices among competing products, and that their incentives
to do so depend on relative margins, goes back at least as far as Telser (1960).5 Similar incen-
tives are likely to be present in many downstream markets, where retailers sell rival products
(e.g., grocery stores, electronic stores, car dealers, etc.), not just in the pharmaceutical market.6
We study the pharmaciesincentives for generic substitution both theoretically and empir-
ically. In the theoretical part, we set up a vertical di¤erentiation model where brand-names
are perceived to be of higher quality than their generic versions. Within this framework we
introduce a (monopoly) pharmacy that may expend e¤ort on persuading consumers to buy a
generic version, for instance, by informing them that the products are therapeutically equiv-
alent.7 We analyse the pharmacys substitution incentives under di¤erent copayment schemes
(i.e., coinsurance and reference pricing) and pricing regimes (i.e., prices are regulated or set by
the pharmacy).
3 Iizuka (2007) studies prescription choices in Japan where physicians also can dispense drugs and pocket the
(regulated) margin. He nds that physicians tend to prescribe drugs with higher margins, but they are also
concerned about the copayments of their patients. Liu et al. (2009) study the same phenonomen in Taiwan.
4Pavcnik (2002) studies the introduction of reference pricing in Germany in 1989, and reports signicant price
reductions on both brand-names and generics. Brekke et al. (2009, 2011) exploit a policy experiment in Norway,
and report large reductions in prices and brand-name market shares, resulting in lower total expenditures and
copayments. See also Aronsson et al. (2001) and Bergman and Rudholm (2003) for similar results in Sweden.
5A recent paper considering such "steering" by retailers is Raskovich (2007), who shows that competition for
steering by upstream suppliers can lead to double-marginalisation.
6A well known argument in the IO literature for common agency is that it facilitates collusion in the downstream
market and is therefore in the interest also of upstream suppliers (Bernheim and Whinston, 1985, 1986). On the
other hand, the retailers ability to steer demand towards more protable products can induce more competition
between suppliers and create a rationale for exclusive dealing. However, the question of common agency versus
exclusive dealing is less of an issue in our setting since such contracts are strictly regulated requiring pharmacies
to store and deliver the full range of pharmaceuticals that are prescribed.
7 In some countries or health plans, generic substitution is mandatory. However, patients can still refuse to
accept a generic version, which means that persuasion still plays a role also under mandatory generic substitution.
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The theoretical analysis o¤ers three main ndings. First, we show that the pharmacys
incentive for generic substitution is higher (i) the larger the generic margin is relative to the
brand-name margin, and (ii) the lower the generic copayment is relative to the brand-name
copayment. If the brand-name margin is higher than the generic margin, the pharmacy has
no incentives to expend e¤ort on generic substitution. Moreover, if the brand-name copayment
is equal to (or even lower than) the generic copayment, the pharmacy would not be able to
convince patients to substitute the prescribed brand-name with a generic version.
Second, we show that pharmacy price setting involves counteracting e¤ects on the generic
substitution e¤ort. A lower, say, brand-name price implies a lower brand-name margin, which
increases the generic substitution e¤ort. However, a lower brand-name price also implies a
lower copayment di¤erence, which makes consumers less willing to accept a generic substitute.
Optimal pharmacy pricing balances these two considerations.
Finally, we show that reference pricing gives stronger incentives for generic substitution
e¤ort than regular coinsurance provided that the distribution of consumerswillingness-to-pay
is characterised by either an increasing or a su¢ ciently weakly decreasing density function. The
reason is that reference pricing induces larger copayment di¤erences between brand-names and
generics, and therefore higher nancial gains for consumers purchasing generics, which implies
that substitution e¤ort by the pharmacy is more e¤ective. This result holds irrespective of
whether prices are regulated or set by the pharmacy.
Based on the theoretical analysis, we derive two testable predictions: (i) a larger di¤erence
between generic and brand-name margins increases the generic market share; (ii) this e¤ect is
stronger in therapeutic markets where drugs are subject to reference pricing. In the empirical
part, we test these two predictions using a unique product-level data set with detailed informa-
tion on all prescription-bound sales in Norway. Our data set is generated by merging two public
register databases from the Norwegian Institute of Public Health containing sales information at
pharmacy level (the Prescription database) and at producer level (the Wholesale database). The
databases are merged by using wholesaler-pharmacy ownership information, which allows us to
compute the product margin for brand-names and generics.8 Our data set covers 70 o¤-patent
8Since most pharmacies (more than 85 percent) in the Norwegian market are vertically integrated with (owned
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substances, where brand-names face competition from generic versions, over a four-year period
from 2004 to 2008.
The descriptive statistics show that brand-names are on average priced higher than generics
both at pharmacy and producer level.9 However, the average brand-name margin is much lower
than the average generic margin, suggesting that pharmacies have a nancial incentive to engage
in generic substitution. We test the relationship between relative product margins and market
shares using xed e¤ects for substitution groups10 and wholesaler (pharmacy chain). Since price
changes at pharmacy (retail) level a¤ects both margins and demand (through the change in
copayments), we control for the pharmacy price di¤erences of brand-names and generics. This
implies that the e¤ect of product margins on market shares is identied by exogenous variation
in the branded-generic producer price di¤erence.
We nd a highly signicant e¤ect of relative brand-name and generic product margins on
market shares. The result conrms our rst prediction that a larger di¤erence between generic
and brand-name margins increases the generic market share due to pharmacies substitution ef-
fort. We also nd that the e¤ect is stronger for pharmaceuticals subject to reference pricing
rather than regular coinsurance, which suggests that pharmacy substitution e¤ort is more e¤ec-
tive when the copayment di¤erence is larger. This result is consistent with our second prediction.
We check the robustness of our results in various ways. One issue is endogeneity in pharmacy
pricing as a response to changes in producer prices. We deal with this by using Danish pharmacy
prices as instruments, and show that the results are qualitatively the same.
In terms of policy implications, our analysis highlights the importance of taking pharmacy
incentives into account when designing the optimal regulatory scheme for the pharmaceutical
industry. Since brand-names are generally priced higher than their generic versions, regressive
mark-up regulation at pharmacy level is a necessary and powerful regulatory instrument to
incentives generic sales at pharmacy level. However, pharmacy incentives needs to be matched
by) three di¤erent wholesalers, we compute the joint wholesaler-pharmacy product margin.
9Consistent with previous studies, we also observe that higher priced brand-names maintain fairly large market
shares despite facing competition from lower priced generic versions that are therapeutically equivalent drugs (see,
e.g., Grabowski and Vernon, 1992, Frank and Salkever, 1997, Pavcnik, 2002, Brekke et al., 2009, 2011).
10Substitution groups are dened by the regulator (Norwegian Medicines Agency) and specify the set of products
that pharmacies can substitute. This is typically generic products with same substance, strength and presentation
form as the brand-name.
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with an appropriate copayment scheme where patient nancially benet from purchasing generic
versions. Our results show that reference pricing provides stronger incentives than regular
coinsurance for pharmacies to promote generic products. Thus, when taking pharmacy incentives
into account, the cost-saving e¤ect of reference pricing might be even higher than previously
thought.
The rest of the paper is organised as follows. In Section 2 we present a theoretical model
of pharmacy incentives and derive some key results regarding the relationship between margins
and market shares for brand-name and generic drugs. Section 3 describes the institutional back-
ground and the Norwegian pharmaceutical market. In Section 4 we present data and descriptive
statistics, while Section 5 describes our empirical method and results. In Section 6 we briey
discuss policy implications before the paper is concluded in Section 7.
2 A theoretical model of pharmacy incentives
There is a total mass of 1 consumers, each with a prescription for the same brand-name drug that
is dispensed by a pharmacy. There is also a generic copy-drug available in case the consumer
wants to substitute. Consumers di¤er in their willingness-to-pay for drugs. The net utility of
drug consumption is given by
U =
8><>: v   cb if brand-namev   cg if generic ; (1)
where v is distributed on [v; v] with a density function f (v) and a corresponding cumulative
distribution function F (v) =
R v
v f (x) dx. The parameter  2 (0; 1) represents the quality
degradation that consumers attribute to the generic version of the drug, while cb and cg are the
copayments of the brand-name and generic drug, respectively. We assume that v > cg , implying
that the market fully covered (i.e., total demand is inelastic and equal to 1). The demand for
6
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the two drug versions are then given by Dg = F (bv) and Db = 1  F (bv), where
bv =
8>>>><>>>>:
v if cb   cg  (1  ) v
cb cg
1  if cb   cg 2 ((1  ) v; (1  ) v)
v if cb   cg  (1  ) v
: (2)
Thus, consumers are willing to buy the generic drug only if it involves a lower copayment.
Otherwise, everybody purchases the brand-name drug. The demand sensitivity with respect to
copayments crucially depends on the perceived quality di¤erence: a lower  implies less demand
sensitivity.
The producer prices of the brand-name and generic drugs are, respectively, wb and wg. Since
pharmacies generally have a stronger bargaining position towards producers of generics, it is
reasonable to assume that wb > wg.11 Assume further that pharmacies can expend e¤ort towards
the individual consumer in persuading her to accept generic substitution. More specically,
assume that the perceived quality degradation of the generic drug () depend on the e¤ort e
(measured in monetary terms) exerted by the pharmacy:  (e), where 0 (e) > 0, 00 (e) < 0 and
 (0) =  2 (0; 1).
Denoting the retail prices of the brand-name and the generic drugs by pb and pg, respectively,
the prot of the pharmacy is given by
 = mbDb +mgDg   e; (3)
where mb := pb   wb and mg := pg   wg are the margins of the brand-name and generic drug,
respectively. We assume throughout the analysis that the producer prices are exogenously given.
In the following, we rst analyse the pharmacys incentives for exerting substitution e¤ort for
given retail prices (subsection 2.1), before extending the analysis to consider the case where the
pharmacy also set retail prices (subsection 2.2). Finally, we derive some testable implications in
11 In the context of pharmacy incentives for generic substitution, the case of wb < wg, besides being less realistic,
is also less interesting, since this implies that pharmacies would have no incentives for generic substitution as long
as the retail price of generics is at or below the retail price of the brand-name drug (which is the realistic price
regime).
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subsection 2.3.
2.1 Substitution incentives with exogenous retail prices
Suppose that retail prices are exogenously given. The optimal choice of substitution e¤ort in an
interior solution is implicitly given by12
@
@e
=
(mg  mb) (cb   cg) f (bv) 0 (e)
(1  )2   1 = 0: (4)
As we can see directly from (4), a strictly positive substitution e¤ort requires that (i) the margin
is higher for the generic than for the brand-name product, and (ii) the brand-name copayment
is larger than the generic copayment. Otherwise, if mg < mb or cb < cg, the pharmacy has no
incentive to spend e¤ort on persuading consumers to switch to the generic version. From (4) it
follows directly that the optimal substitution e¤ort (in an interior solution) increases with the
generic-branded di¤erence in margins (mg  mb). Notice also that the amount of substitution
e¤ort undertaken depends on the density of demand around the indi¤erent consumer, which
gives a measure of how many consumers that can potentially be persuaded to switch from the
brand-name to the generic drug.
More interesting is perhaps the e¤ect of the copayment system on substitution incentives.
Assuming an interior solution, e > 0 such that bv (e) 2 (v; v), the qualitative e¤ect of a marginal
increase in the branded-generic copayment di¤erence (cb  cg) on optimal substitution e¤ort can
be derived from (4), and is given by
sign

@e
@ (cb   cg)

= sign

@2
@ (cb   cg) @e =
(mg  mb) 0 (e)
(1  )2

f (bv) + (cb   cg)
1   f
0 (bv) : (5)
A marginal increase in the copayment di¤erence has two di¤erent (and potentially counteracting)
e¤ects on substitution incentives. These two e¤ects are represented by the two terms in the
square brackets of (5). First, a larger copayment di¤erence implies that a given increase in
12The second-order condition is
@2
@e2
=
(mg  mb) (cb   cg)
(1  )3

f 0 (bv) [0 (e)]2
1   + f (bv) (1  ) 00 (e) + 2[0 (e)]2

< 0:
8
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 has a larger e¤ect on bv. In other words, a larger copayment di¤erence makes it easier to
convince consumers with preferences in the neighbourhood of bv to switch from the brand-name
to the generic drug. All else equal, this increases the pharmacys incentive to exert substitution
e¤ort. However, a larger copayment di¤erence also increases bv directly; i.e., it means that
the indi¤erent consumer has a higher willingness to pay for drug treatment. Thus, even if an
increase in (cb   cg) means that it takes less e¤ort to persuade a given consumer to accept
generic substitution, the number of consumers that can potentially be persuaded to make the
substitution (i.e., the density of consumers in the neighbourhood of bv) might be higher or lower.
The total e¤ect of copayment di¤erences on substitution incentives therefore depends on the
distribution of v. If consumer density is increasing in v, both e¤ects go in the same direction
and a larger copayment di¤erence unambiguously leads to higher substitution e¤ort. However, if
the density is decreasing in v, and at a su¢ ciently high rate, a higher copayment di¤erence might
lead to lower substitution e¤ort instead. This will be the case if the reduction in the number
of consumers that can potentially be persuaded to accept generic substitution is su¢ ciently
large to outweigh the e¤ect that these consumers become easier to persuade. Notice also that
@e
@(cb cg) > 0 if and only if
@[(cb cg)f(bv)]
@(cb cg) > 0. If this condition holds, it follows directly from (4)
that a larger copayment di¤erence will also reinforce the positive relationship between relative
margins (mb  mg) and substitution e¤ort.
Proposition 1 (i) The optimal substitution e¤ort in an interior solution is increasing in the
di¤erence in margins between generics and brand-names (mg mb). (ii) If f (bv)+ (cb cg)1  f 0 (bv) >
0, a marginal increase in the copayment di¤erence (cb   cg) leads to higher substitution e¤ort
and reinforces the e¤ect stated in (i).
Suppose that f (v) is either increasing or su¢ ciently weakly decreasing, such that f (bv) +
(cb cg)
1  f
0 (bv) > 0. In this case, the second part of Proposition 1 has clear-cut implications for
the e¤ects of di¤erent types of copayment systems on generic substitution. Consider a simple
coinsurance regime, where the copayment is dened as
ci = pi + k; i = b; g; (6)
9
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where  2 (0; 1) is the coinsurance rate and k is a deductible. With this copayment scheme,
the branded-generic copayment di¤erence is given by cb  cg =  (pb   pg). Thus, the higher the
coinsurance rate (), the higher is the optimal substitution e¤ort and the stronger is the e¤ect
of relative margins on substitution incentives.
Another widely used copayment regime is reference pricing, where consumers have to pay the
full price di¤erence between generic and brand-name drugs if choosing to purchase the latter.
In this case, the copayment schedule is given by
ci =
8><>: r + (pb   r) + k if i = bpg + k if i = g ; (7)
where r 2 (pg; pg) is the reference price. The branded-generic copayment di¤erence is now given
by cb   cg = pb   pg   (1  ) r. We see that, compared with a simple coinsurance scheme
(r = pb), reference pricing (r < pb) increases the branded-generic copayment di¤erence. Thus,
for given retail prices, and as long as f (v) is either increasing or su¢ ciently weakly decreas-
ing, reference pricing increases the optimal substitution e¤ort and strengthens the relationship
between relative margins and substitution incentives.
The above analysis applies for the case of exogenously given retail prices. In the next sub-
section we analyse incentives for generic substitution when the pharmacy can also set the retail
prices of the generic and brand-name drugs. In order to facilitate the analysis, we assume that
consumerswillingness to pay for drug treatment is uniformly distributed on [v; v], implying
f (v) = 1v v and f
0 (v) = 0. From Proposition 1 we know that this assumption establishes an
unambiguously positive relationship between the copayment di¤erence and the optimal substi-
tution e¤ort.
2.2 Substitution incentives with endogenous retail prices
If the pharmacy can set retail prices, it has another instrument to steer demand towards the
most protable drug version. Given that copayments depend on prices, demand for the two
drugs depend on the retail price di¤erence between the brand-name and the generic drugs. For
10
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a given value of , the pharmacy faces the following trade-o¤ when deciding the optimal retail
price di¤erence. If pb = pg, the generic drug is more protable for the pharmacy to sell (since
wg < wb), but in order to make consumers choose the generic drug, it has to be priced lower
than the brand-name. The further pg is reduced below pb, the larger is the share of consumers
choosing the generic. However, lowering pg reduces the protability of selling the generic drug.
Thus, the pharmacy maximises prots by choosing a branded-generic retail price di¤erence that
optimally trades o¤ these two incentives.
As long as total demand is inelastic, the pharmacy would obviously want to set the optimal
price di¤erence at the highest possible level. Thus, we assume that retail price setting is restricted
by price cap regulation, that species the highest possible retail price that the pharmacy can
set. From the above discussion, if follows that the price cap always binds for the brand-name
drug. In the following, we will briey discuss optimal retail price setting and implications for
substitution incentives under di¤erent copayment scenarios.
2.2.1 Simple coinsurance
Assume that copayments are given by (6). Maximising (3) with respect to pg, the optimal retail
price di¤erence is given by
pb   pg = (wb   wg)
2
+
(1  ) v
2
: (8)
Notice that the retail price di¤erence is constant, implying that any change in the brand-name
retail price (e.g., due to stricter price cap regulation) will be exactly matched by a corresponding
change in the generic retail price.13 Demand for the generic drug is given by
Dg =
 (wb   wg)  (1  ) v
2 (v   v) (1  ) : (9)
13This property follows from the assumptions of full market coverage and uniform distribution of v.
11
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Inserting the optimal price di¤erence into (4), with f (v) = 1v v , the rst-order condition for
optimal substitution e¤ort is given by
 (wb   wg)2 0 (e)
4 (v   v) (1  )2   1 = 0: (10)
When the generic price is optimally adjusted, substitution e¤ort depends only on the branded-
generic producer price di¤erence. A higher producer price for the brand-name (generic) drug
will increase (reduce) substitution e¤ort. If we consider the relationship between producer prices
and market shares, pharmacy incentives for expending substitution e¤ort will have reinforcing
e¤ects when the branded-generic retail price di¤erence is endogenous. A reduction in the brand-
name (generic) producer price leads to an increase (reduction) in the generic retail price, which
directly increases demand for the brand-name (generic) drug. This e¤ect is reinforced by the
fact that the pharmacy will spend less (more) e¤ort on generic substitution.
2.2.2 Reference pricing
Consider a reference pricing scheme where copayments are given by (7). Assuming that r 2
(pg; pb), the optimal generic retail price (hence implicitly the optimal retail price di¤erence), is
given by
pg =
(1 + ) pb   (1  ) r    (wb   wg)  (1  ) v
2
: (11)
This price is indeed below the reference price if pb < r+
(wb wg)+(1 )v
1+ . Demand for the generic
drug is now
Dg =
(1  ) (pb   r) +  (wb   wg)  (1  ) v
2 (v   v) (1  ) : (12)
If r = pb, this solution is obviously identical to the solution under a simple coinsurance system.
Thus, we can analyse the e¤ect of reference pricing by considering a marginal reduction in r,
evaluated at r = pb. The e¤ect on the optimal retail price is given by
@pg
@r =  1 2 < 0, implying
that reference pricing reduces the optimal price di¤erence between brand-names and generics.
The reason is that reference pricing increases consumer incentives for generic substitution, as
the demand becomes more price sensitive above the reference price. However, this means that
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the pharmacys optimal substitution e¤ort increases, since the di¤erence in margins becomes
larger (due to the higher generic retail price). This is easily seen by substituting pg from (11)
into the rst-order condition for optimal substitution e¤ort, yielding:14
((1  ) (pb   r) +  (wb   wg))2   ((1  ) v)2
4 (v   v) (1  )2  
0 (e)  1 = 0: (13)
Proposition 2 If pharmacies are free to set retail prices (but subject to price cap regulation)
and if consumerswillingness to pay for drug treatment is uniformly distributed, the introduction
of reference pricing will reduce the retail price di¤erence between brand-names and generics and
increase the pharmacys optimal choice of substitution e¤ort.
The rst result, that reference pricing reduces the branded-generic price di¤erence is in line
with a previous result shown, and also empirically conrmed, by Brekke et al. (2011). The
second result, that reference pricing leads to higher substitution e¤ort, is consistent with the
result reported in the second part of Proposition 1 and shows that, at least for a uniform
distribution of v, the positive e¤ect of reference pricing on substitution e¤ort holds regardless
of whether retail prices are exogenous or not. This suggests that the positive e¤ect of reference
pricing on generic market shares previously reported in the literature (see, e.g., Brekke et al.,
2011) could be partly explained by increased substitution e¤ort of pharmacies.
2.3 Testable implications
We are interested in the pharmaciesrole in promoting generic competition. In particular, we
analyse the relationship between pharmacies nancial incentives (product margins) and the
market shares of brand-names and generics. Pharmacies would of course prefer to sell generics
if the generic (brand-name) margin is higher than the brand-name margin, and vice versa.
Our theoretical model argues that generic substitution is costly for the pharmacies, since they
14 It is straighforward to show that our results are qualitatively similar if we endogenise the reference price and
let it be a function of actual drug prices in the market, for example by the formula
r = pg + (1  ) pb;
where  2 (0; 1). See Brekke et al. (2011) for a more thorough analysis of the di¤erence between exogenous and
endogenous reference pricing.
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need to persuade patients. Product margins are therefore crucial for pharmacies incentives
to expend promotional e¤ort on generic substitution. Our data allow us to observe product
margins and generic sales at pharmacy level. However, the pharmaciese¤ort related to generic
substitution is generally hard to observe. Creating a good measure of such e¤ort would require
detailed information on the time spent by pharmacists at the dispensing point. A more crude
measure would be to observe the frequency of generic substitution, which would require detailed
information about the prescriptions made by the physician, especially whether a brand-name
was prescribed, and the purchase made by the patient. Unfortunately, we do not have this kind
of detailed information. Our empirical strategy will therefore be to use the relationship between
product margins and market shares (brand-name versus generic). This strategy is based on the
following theoretical implications of the above analysis.
Assuming that the brand-name drug is subject to (binding) price cap regulation, implying
that pb is exogenous (along with wb and wg), the optimal generic retail price and the optimal
promotion e¤ort, denoted by pg (pb; wb; wg) and e (pb; wb; wg) are given by the simultaneous
solution to (4) and (8) under simple coinsurance, and (4) and (11) under reference pricing. The
demand for generics can therefore be expressed, on general form, as
Dg
 
pb; p

g (pb; wb; wg) ;  (e
 (pb; wb; wg))

:
Since total demand is assumed to be perfectly inelastic, there is a one-to-one relationship between
demand for the generic drug and its market share. Thus, the e¤ect of a marginal increase in the
brand-name producer price on the generic market share is given by
@Dg
@wb
=
@Dg
@pg
@pg
@wb
+
@Dg
@
0 (e)
@e
@wb
> 0: (14)
Both terms on the right-hand side of (14) are positive. The rst term is the demand e¤ect caused
by a change in the copayment di¤erence between brand-name and generic drugs, for a given level
of substitution e¤ort. An increase in the brand-name producer price will lead to a drop in the
generic retail price, regardless of whether the copayment scheme is based on simple coinsurance
14
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or reference pricing (cf. (8) and (11)). The drop in pg makes the brand-name drug relatively
more expensive and increases the generic market share. The second term is the demand e¤ect
caused by a change in substitution e¤ort. For given retail prices, an increase in the brand-name
producer price increases the di¤erence in product margins between generics and brand-names,
which increases the pharmacys optimal choice of e¤ort (cf. Proposition 1).
Thus, an increase in the brand-name producer price increases the generic market share
through two di¤erent channels: a lower generic retail price and a higher substitution e¤ort.15
However, since e¤ort is unobservable, it is not possible to estimate the second e¤ect directly.
What we can do instead is to estimate the e¤ect of changes in producer prices on market shares,
controlling for retail prices. This allows us in principle to isolate the second e¤ect, since, for
given retail prices, a change in producer prices is equivalent to a change in product margins
only, which a¤ects the pharmacys incentives for promoting generics but does not a¤ect relative
copayments. If pharmacies are not willing or able to spend e¤ort on persuading consumers
to switch from brand-names to generics, we would not expect to nd any e¤ect of changes in
product margins on market shares, when controlling for retail prices.
Given that the density of patients is either increasing or su¢ ciently weakly decreasing in
the willingness-to-pay for drugs, our theoretical analysis also shows that the e¤ect of a change
in product margin di¤erences between brand-names and generics on optimal promotion e¤ort
is larger under reference pricing than under a simple coinsurance system (cf. Proposition 1 in
conjunction with (7)). In other words, the second term in (14) is larger if the copayment system
for drugs is based on reference pricing.
Relying on the assumption that f (v) is either increasing or su¢ ciently weakly decreasing,
our theoretical analysis therefore allows us to formulate two predictions that can be tested with
our data:
(i) A larger di¤erence in margins between generics and brand-names increases the market
share of generics;
15 It is straightforward to show that an increase in the generic producer price has the exact opposite e¤ect: it
increases the generic retail price and reduces the substitution e¤ort, leading to a lower generic market share.
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(ii) The e¤ect postulated in (i) is stronger in therapeutical markets where drugs are subject
to reference pricing.
3 Institutional Background
The Norwegian pharmacy market was liberalised in 2001. Before the liberalisation, entry and
location were determined by a governmental health agency, and ownership was restricted to
pharmacists. The new act removed these restrictions, making Norway one of the pioneers in
Europe in this regard. Most European countries still have strict restrictions on entry and
ownership, though the European Commission is pushing for deregulation of the pharmacy sector.
The liberalisation in Norway caused dramatic changes to the pharmacy market structure.
Almost over night most of the about 400 pharmacies owned by self-employed pharmacists were
sold to three international wholesalers. The three wholesalers are Norsk Medisinaldepot (owned
by Celesio AG), Alliance Healthcare (owned by Alliance Boots Ltd) and Apokjeden (owned
by Tamro Oy and Phoenix AG). Besides purchasing existing pharmacies, the wholesalers have
established many new pharmacies, especially in non-rural areas. The number of pharmacies
increased to 662 in 2009, which is an increase of almost 70 percent since 2001.
[ Table 1 about here ]
As can be seen from Table 1, the four pharmacy chains Alliance, Apotek 1, Vitusapotek
and Ditt Apotek cover more than 96 percent of the total number of pharmacies. Three of
these chains (Alliance, Apotek 1, and Vitusapotek) consist of pharmacies that are owned by
the wholesalers. The fourth chain (Ditt Apotek) is a franchise of Norsk Medisinaldepot. The
remaining pharmacies are independent of the wholesalers, but purchase their products from the
wholesalers. The three wholesalers cover the whole pharmacy retail market for pharmaceuticals.
The pharmaceutical market is extensively regulated, which has implications for market struc-
ture and rm behaviour. First, pharmaceutical producers cannot have ownership in pharmacies,
and vice versa. This is a common restriction in Western countries. Second, wholesalers are
16
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required to store and deliver the full range of pharmaceuticals that are demanded by patients
(prescribed by doctors).16 This implies that wholesalers must carry both brand-names and
generics and cannot exclusively o¤er either. Third, the demand for prescription drugs is sub-
sidised at the point of consumption due to medical insurance. Patients pay only a fraction (36
percent) of the drug price. However, the patients copayments are restricted by expenditure
caps. Once these caps are reached, the government covers 100 percent of the additional medical
expenditures. According to LMI (2009) the de facto patient copayment is about 30 percent of
the total pharmaceutical spending. Fourth, prescription drug prices are subject to price cap
regulation. The maximum price for a given drug is based on international price comparisons
(external referencing) and imposed at wholesale level.17 The price cap at pharmacy retail level
is derived by adding a regulated mark-up that pharmacies are allowed to charge. Notably,
brand-names and generics face the same price cap, but in practice the price cap is usually only
binding for the higher priced brand-names. The prices at producer (ex-manufacturer) level are
not subject to regulation.
In 2003 the government introduced reference pricing (internal referencing) for a subsample
of the o¤-patent molecules with generic competition. This system has been extended to all new
molecules for which the patent expires and generic competition takes place.18 The reference
price, which is the maximum reimbursement for all products with a given molecule, is dened
as a "discount" on the price cap for this molecule.19 The rms are free to charge prices above
the reference price (though constrained by the price cap). However, if a product is priced above
the reference price, patients that demand this drug must pay the di¤erence between the charged
price and the reference price out-of-pocket (in addition to coinsurance). This price di¤erence
16"Important" drugs should be delivered within 24 hours, while less important drugs have a 48 hour delivery
deadline.
17Producers must report their prices in nine reference countries (Austria, Belgium, Denmark, Finland, Germany,
Irland, the Netherlands, Sweden and United Kingdom). The price cap is dened as the average of the three lowest
prices in the reference countries and updated annually.
18There has also been a modication of the reference price system. The rst version called "indekspris" dened
the reference price as a sales weighted sum of brand-name and generic prices (see Brekke et al., 2009, 2011). This
system was replaced by "trinnpris" in January 2005, where the reference price is calculated as a discount on the
price cap prior to generic competition.
19The discount is progressive. First, the reference price is 70 percent of the price cap before generic competition.
Then after 6 months the reference price is reduced to 45 or 25 percent depending on it sales value. Finally, after
18 months the reference price is reduced to 35 or 20 percent.
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will not be covered by the public insurer even if the patients medical costs have reached the
expenditure cap. The intention is to induce consumers to substitute to a lower priced generic
and/or get the brand-name producer to reduce its price.
4 Data and descriptive statistics
For the empirical analysis, we have obtained register data from the Norwegian Institute of Public
Health. Our data are extracted from two di¤erent databases; the Prescription and the Wholesale
database. The Prescription database contains information about all prescription bound sales at
pharmacy level in Norway from 2004 and onwards. From this database we have obtained data
on average prices and volumes per month over a four-year period (2004-7). Prices and volumes
are in dened daily doses (DDD) per product per pharmacy. The data also contain detailed
information about product name, manufacturer, launch date, pack size, strength, presentation
form (e.g., tablet, capsule, injection), etc. The Wholesale database contains information about
producer (ex-manufacturer) prices (in DDD) per product per wholesaler per month. In order
to merge these two data sets we have obtained detailed information about ownership and chain
a¢ liation of each pharmacy for the sample period.
In order to study pharmacies generic substitution incentives, we have generated a data
set with 70 o¤-patent substances, where brand-names face de facto competition from generic
versions.20 However, since pharmacies are only allowed to substitute products with the same
substance, strength and presentation form, we aggregate our data at substitution group level.
The substitution groups are dened by the regulator (Norwegian Medicines Agency) and specify
the set of products that pharmacies are allowed to dispense to patients with a prescription
of a given (brand-name) drug.21 Basing the analysis on substitution group level rather than
substance level, allows us to more precisely estimate the impact of pharmaciesproduct margins
on the sales of brand-names and generics.
The empirical analysis includes all vertically integrated pharmacies. As shown in the previous
20Table A1 in the Appendix provides a complete list of the set of substances in our sample, as well as descriptive
statistics of our key variables.
21 In Table A1 in the Appendix, we report the number of substitution groups for each substance.
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section, 85 percent of the pharmacies on the Norwegian market are owned by the wholesalers,
which means that our data covers most of the prescription bound sales. The relevant margin for
this set of pharmacies is the joint wholesaler-pharmacy margin. Focusing only on the pharmacy
margin itself is of less interest, since the pharmacy purchasing price is simply an internal price
in the vertically integrated rm.22
The joint wholesaler-pharmacy margin is dened as the di¤erence between the pharmacy
retail price and the producer (ex-manufacturer) price. For each of the three wholesalers, we
calculate separate brand-name and generic prices and market shares as averages for each sub-
stitution group. At retail level this implies that we aggregate prices and market shares across
pharmacies owned by the same wholesaler.23
Table 2 below provides an overview of the means and standard deviations of our key variables
across the three pharmacy chains, as well as the industry gures.24
[ Table 2 about here ]
The table shows an average brand-name market share for the industry of 41.9 percent, but with
di¤erences across wholesalers, varying from 34.1 to 45.6 percent. Notice also that Table A.1 in
the Appendix reports considerable variation in brand-name market shares across substances. As
expected the brand-names are consistently priced higher than the generics at both producer and
retail level. This pattern is consistent across the wholesalers. In line with our theory, we see that
the generic margin is substantially higher than the brand-name margin. At industry level the
average generic margin is NOK 8.22 at industry level, while the average brand-name margin is
NOK 5.35. The margin di¤erences, dened as the generic margin net of the brand-name margin,
vary from NOK 2.46 to NOK 3.57 across the wholesalers.25
22Alternatively, we could have considered the independent pharmacies, but this would have required information
about pharmacy purchasing prices, which is not available.
23To check that our results are not sensitive to aggregation bias, we have also aggregated data at pharmacy
level. The results are qualitatively similar to the ones reported in Table 3 in Section 5, and are available upon
request.
24Table A.1 in the Appendix report the same gures for each substance in our sample.
25While the generic margins are higher than the brand-name margins on average, this is not the case for every
substance. As can be seen from Table A1 in the Appendix, for 9 out of 70 substances the margin di¤erence is
negative.
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Since we are interested in the relationship between the (di¤erence in) product margins and
market shares, it is useful to see how these variables develop over time. In Figure 1-3 we plot
the changes in our key variables for each of the three wholesalers for the four-year period from
2004 to 2007. The gures are based on products in substitution groups that are present in our
sample for the whole period. The reason is that entry and exit of products (substitution groups)
shift margins and market shares, so that trends would be hard to detect from the gures.26
[ Figures 1-3 about here ]
The gures show a clear tendency. The average margin di¤erence increases over time, whereas
the average brand-name market share decreases over time. The trends are fairly similar for
wholesalers 1 and 3. The brand-name market share drops from about 45-50 percent down to
around 30 percent, while the margin di¤erence increases from around 0.4 NOK up to 1 NOK.
For wholesaler 2 the picture is somewhat di¤erent. The initial brand-name market share is
higher (around 65 percent), and the increase in the margin di¤erence is stronger (about 1 NOK)
in the rst part of the period. In the second part of the period, the brand-name margin and
the margin di¤erence tend to stabilise at the same level as wholesaler 1 and 3. The descriptive
statistics in Table 2 and the graphs in Figure 1-3 indicate a relationship between the margin
di¤erence between generics and brand-names and their market shares. We take a closer look at
this in the next section.
5 Empirical method and results
In this section we aim at testing the two main predictions from the theoretical analysis: (i)
a larger di¤erence in the margins between generics and brand-names decreases (increases) the
market share of brand-names (generics); and (ii) the e¤ect postulated in (i) is stronger in ther-
apeutical markets where drugs are subject to reference pricing. To test the rst prediction, we
estimate the following xed e¤ect model:
26About 50 percent of the products (substitution groups) are present in our data for the whole period. Thus,
the gures should be fairly representative for our sample.
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Yikt = + mikt + pikt + RPit + si + !k + t + "ikt; (15)
where Yikt is the market share of brand-names within substitution group i at pharmacies belong-
ing to wholesaler k at time t. In the regression we include xed e¤ects for substances (si) and
wholesalers (!k). The substance xed e¤ects capture time-invariant, unobserved (and observed)
factors that a¤ect the market shares of brand-names. This could be substance characteristics
such as the share of brand-loyal consumers (or physicians), type of patients (age, gender), type
of disease (chronic or acute), type of product (tablet, capsule, injection), etc. The wholesaler
xed e¤ects capture time-invariant factors that inuence the brand-name market shares. This
may include wholesaler characteristics such as pharmacy chain proles, marketing strategies,
distribution costs, pharmacy locational patterns (urban vs. rural), etc. We also include a time
dummy t that captures time trends in brand-name market shares that are common across sub-
stances and wholesalers, and dummy for whether or not the products are subject to reference
pricing (RP ).
We are interested in estimating the impact of the margin di¤erence between brand-names and
generics (mikt) on their market shares. In doing so, it is important to control for the di¤erence
between brand-name and generic prices at pharmacy (retail) level (pikt). The reason for this is
that a change in the pharmacy prices a¤ects both the margin and the copayment, as explained
in the theory section. Thus, controlling for the demand e¤ect of copayment changes is therefore
important in order to consistently estimate the impact of margins on market shares.27
Including pharmacy (retail) price di¤erences in the regression implies that the e¤ect of mar-
gins on market shares are identied by the brand-name and generic prices at producer level. To
see this, we can write margin di¤erence as follows:
m := (pb   wb)  (pg   wg) = (pb   pg) + (wg   wb) :
27We use the pharmacy price di¤erence as a proxy for the copayment di¤erence. As shown in Section 2, a one
unit change in the price di¤erence leads to an  unit change in the copayment di¤erence, with  2 (0; 1) being the
coinsurance rate. The relationship is stronger under reference pricing, but still less than one. Using the pharmacy
price di¤erence may therefore imply that we underestimate the e¤ect of copayments on market shares. Moreover,
since pharmacy price changes also inuence the margins, we cannot rule out that this variable also includes a
margin e¤ect.
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Thus, controlling for the pharmacy price di¤erence implies that the margin di¤erence is equiva-
lent to the di¤erence in producer prices. Using the margin di¤erence directly would not generate
any problems for the interpretation of the e¤ect of margins on market shares. However, the in-
terpretation of the e¤ect of the pharmacy price di¤erence would be unclear. We therefore dene
mikt as the di¤erence between the generic and the brand-name producer prices (wg   wb).
The results from the xed e¤ect regressions are reported in Table 3. In these models we
implicitly assume that the di¤erences in producer prices (margins) and pharmacy retail prices
are exogenous. In Section 5.2 we address potential endogeneity problems.
[ Table 3 about here ]
Our results (Model 1) indicate signicant e¤ects of di¤erences in the pharmaciesmargins on
generic and brand-name products on the brand-name market shares. As mentioned above, we
measure the di¤erence in pharmacy margins by the di¤erence between generics and brand-name
producer prices, which means that a larger producer price di¤erence is equivalent to a lower
margin on generics relative to the brand-name.28 Our results show that a 1 NOK increase in
the producer price di¤erence (i.e., a 1 NOK reduction in the margin di¤erence between generics
and brand-names) leads to a 0.49 percentage points increase in the brand-name market shares.
The pharmacy price di¤erence has the expected e¤ect on market shares. A 1 NOK increase in
the pharmacy price (copayment) di¤erence between brand-name and generics is associated with
a 0.77 percentage point reduction in the brand-name market share. These empirical results are
consistent with our rst prediction from the theoretical analysis.29
28Estimating the model using the margin di¤erence gives obviously the same results, but the coe¢ cient associ-
ated with the pharmacy price di¤erence variable becomes harder to interpret, as explained above.
29We have performed a number of robustness analyses: (i) control for the number of generics per substance per
period; (ii) estimate more exible specications where we allow for non-linear e¤ects of pharmacy price di¤erences,
and also allow price di¤erences to have di¤erent e¤ects in di¤erent periods; and (iii) include substance-specic
time trends. In each of these alternative specications, the main results (which are available upon request) remain
qualitatively similar to the ones reported in Table 3.
22
SNF Working Paper No 08/13
5.1 The role of the copayment structure
Our theoretical analysis pointed out that the copayment structure a¤ects the pharmaciessub-
stitution incentives. The pharmaceuticals in our data are either under standard coinsurance or
reference pricing. Table A.1 in the Appendix shows which substances were subject to reference
pricing and when they were included in the scheme. Based on the theoretical analysis, we expect
pharmacies to expend more e¤ort on persuading consumers to switch to generics under refer-
ence pricing, since, for a given retail price di¤erence, the copayment di¤erence is larger under
reference pricing than under simple coinsurance. Thus, there should be a stronger relationship
between brand-name and generic product margins and their market shares for the drugs that
are exposed to reference pricing. To test this we interact the margin di¤erence with a reference
pricing dummy:
Yikt = + 1mikt + 2mikt RPit + pikt + RPit + si + !k + t + "ikt (16)
The results are reported Table 3 (Model 2). We see that the e¤ect of the producer price
(margin) di¤erence on the brand-name market share is substantially higher for products under
reference pricing. A 1 NOK increase in the producer price di¤erence (i.e., a 1 NOK decrease in
the margin di¤erence between generics and brand-names) is associated with a 1.37 percentage
point increase in the brand-name market share. For products under regular coinsurance, a similar
change in the margin di¤erence is associated with only a 0.58 percentage point increase in the
brand-market share. This nding is consistent with the second prediction from our theoretical
analysis.
5.2 Asymmetric e¤ects
In our theoretical model, we have implicitly assumed that pharmacies can spend e¤ort to per-
suade, but never to dissuade, consumers to buy a generic drug instead of the brand-name. This
implies that changes in product margins should only a¤ect market shares within substitution
groups where generic margins are higher than the brand-name margin. However, for substitu-
tion groups where the margin is higher for the brand-name drug, the pharmacy may have an
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incentive to dissuade consumers who ask for generic substitution themselves, or to recommend
the brand-name drug to patients who enter the pharmacy with a prescription for a generic
drug. We test for the potential existence of asymmetric e¤ects along these lines by including a
dummy variable that takes the value 1 for products which belong to substitution groups where
the brand-name margin is higher than the generic margin and 0 otherwise, and interacting this
variable with the producer price di¤erence mikt. The results are shown in Table 4.
[ Table 4 about here ]
We see that the e¤ect of an increase in the producer price di¤erence (between generics and
brand-names) on the brand-name market share is positive for both types of substitution groups,
but the e¤ect is signicantly stronger for substitution groups where the generic margin is higher
(0:470 compared with 0:470  0:159 = 0:311 ). These results suggest that the promotional e¤ort
of pharmacies is mainly directed towards persuading consumers to accept generic substitution.
A plausible explanation for these asymmetric e¤ects is that explicitly dissuading consumers from
generic substitution can be perceived as a violation of government regulations and such activities
will therefore be associated with a higher disutility of e¤ort for the pharmacy.
5.3 Potential endogeneity
Controlling for pharmacy retail price di¤erences when estimating the e¤ect of changes in pro-
ducer prices on market shares gives rise to an endogeneity problem. If pharmacies respond to
changes in producer prices by changing the pharmacy retail prices, this may lead to inconsistent
estimates of the e¤ect of margins on market shares. The reason is that in this case we cannot
assume the pharmacy price di¤erence to be xed.
As previously described, the brand-name pharmacy prices are usually capped by regulation,
and thus exogenous. However, as explained in the theory section, pharmacies have an incentive to
respond to changes in producer prices by optimally adjusting the generic retail prices. Therefore,
the pharmacy retail price di¤erence is likely to be endogenous.
A common way to deal with endogenous explanatory variables is to use IV regression. To
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consistently estimate the e¤ect of changes in margin di¤erences on market shares we need an
instrument variable that is correlated with pharmacy retail price di¤erences, but not with the
market shares. We use Danish pharmacy retail price di¤erences as instruments. The price
data are collected from a publicly available database provided by the Danish regulatory agency
(Lægemiddelstyrelsen).30 We compute the monthly average brand-name and generics prices
for each substance, and use this to calculate the pharmacy retail price di¤erences in Denmark.
This instrument should be valid. There is no reason to believe that the Danish pharmacy price
di¤erences should inuence the brand-name market shares or the producer price di¤erences in
Norway.
We apply a xed e¤ect IV estimator31 that is robust to, and e¢ cient in the presence of,
arbitrary serial correlation and heteroskedasticity (see Baum, Scha¤er and Stillman, 2007).32
Orthogonality of the instruments is tested by Hansens J statistic, which is consistent in the
presence of heteroskedasticity and autocorrelation (the null hypothesis is that the instruments
are uncorrelated with the error term). However, instrument exogeneity is only one of the two
criteria necessary for instruments to be valid. If the instruments are uncorrelated, or only weakly
correlated, with the endogenous variables, then sampling distributions of the IV statistics are in
general non-normal. In this case, standard IV estimates, hypothesis tests and condence intervals
are unreliable. Hence, tests for underidentication and weak identication are reported.33
The results from the xed e¤ect IV model are reported Table 5 below.34
[ Table 5 about here ]
As seen from the table, we have price data from Denmark for 58 out of 70 substances. The
30These prices can be found at www.medicinpriser.dk.
31 IV models were estimated using the Stata module xtivreg2 (Scha¤er, 2007).
32The long-run heteroskedasticity and autocorrelation consistent covariance matrix is generated using the
Bartlett kernel function with a bandwidth of 12. According to Baum, Scha¤er and Stillman (2007), a common
choice of bandwidth for these kernels is a value related to the periodicity of the data, i.e., 12 for monthly.
33The underidentication test is a Lagrange multiplier (LM) test of whether the excluded instruments are
correlated with the endogenous regressors (the null hypothesis is that the equation is underidentied). The weak
instrument test statistic is based on the Kleibergen-Paap rk statistic. As a rule of thumbthis F-statistic should
be at least 10 for weak identication not to be considered a problem (Staiger and Stock, 1997).
34First step results are available upon request.
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reason that some substances drop out is that either the brand-name or the generic has a 100
percent market share in Denmark. In order to check whether the results are sensitive to this
exclusion, we estimate the same model (Model 1) as presented in Table 3. We see that the
results are almost identical.
As can be seen from Table 5, we estimate two di¤erent IV xed e¤ect regressions. In Model
2 we use the Danish price di¤erences in period t as instruments, while in Model 3 we also include
the price di¤erences in period t 1. The tests indicate that both models are identied, and that
there are no problems with weak instruments. The Sargan-Hansen test in Model 3 fail to reject
the null hypothesis (i.e., the instruments are uncorrelated with the error term), suggesting that
the instruments are valid.
The results from the IV regressions are fairly similar to the ones reported in Model 1. We see
that the e¤ect of the producer price di¤erences on brand-name market shares becomes somewhat
weaker, whereas the e¤ect of the pharmacy retail price di¤erence becomes stronger. This suggests
limited problems with endogenous explanatory variables, and the results are consistent with the
rst prediction from our theoretical analysis.
6 Policy implications
As mentioned in Section 2, the previous literature on generic competition has focused either
on physiciansprescribing practices or on the design of the patient reimbursement system for
prescription drugs. In the present paper, we have found that pharmacy incentives are also likely
to play a crucial role in determining generic sales and thereby total pharmaceutical expenditures.
What are the possible policy implications of this nding? We would here like to emphasise two
di¤erent implications for optimal regulation of pharmaceutical markets that follow from our
analysis.
First, our empirical results indicate that pharmacy margins on branded versus generic drugs
have a sizeable impact on generic market shares. This suggests that mark-up regulation at the
pharmacy level could potentially be an additional powerful instrument in order to stimulate
generic competition and thereby obtain cost savings. However, the important lesson from our
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analysis is that the e¤ect of mark-up regulation on generic competition depends crucially on the
design of the regulation scheme. More specically, a regressive mark-up scheme that provides
lower absolute margins on higher priced drugs (brand-names) will provide pharmacies with
incentives to steer demand towards cheaper generic drugs. On the other hand, a xed percentage
mark-up will automatically imply that pharmacies have higher margins on (higher-priced) brand-
name drugs, which is detrimental for stimulating generic competition. Although these insights
are not new, our empirical analysis suggests that the quantitative impact of qualitatively di¤erent
mark-up schemes is potentially large.
Second, our analysis also casts additional light on the e¤ects of a widely used instrument
for stimulating generic competition, namely reference pricing. In our theoretical model, we
show that reference pricing reinforces pharmacy incentives for expending e¤ort on persuading
consumers to switch from brand-names to generics. We are also able to conrm this e¤ect in our
empirical analysis. Thus, by explicitly taking pharmacy incentives into account, we are able to
identify an additional channel through which reference pricing stimulates generic competition.
Our analysis can therefore be seen as o¤ering an additional argument for introducing reference
pricing (or any other reimbursement scheme that increases the relative patient copayment for
branded versus generic drugs) in order to contain the growth in pharmaceutical spending.
7 Concluding remarks
The functioning of pharmaceutical markets is complex and far from perfectly understood. One
of the most studied yet less understood issues, is that of generic competition in the o¤-patent
market for prescription drugs. Compared to markets for ordinary consumption goods, a compli-
cating factor is that demand for prescription drugs is partly determined as a result of interactions
between prescribing physicians and patients. However, we argue that there are also other com-
plicating, and less understood, factors. In the present paper, we have examined a hitherto
neglected factor in explaining generic competition, namely the role of dispensing pharmacies.
More specically, we have analysed theoretically and empirically the incentive for pharmacies
to promote generic instead of brand-name drugs.
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Based on a theoretical model of vertical di¤erentiation, we show that pharmacy incentives
to steer demand towards generic drugs are increasing in the product margin di¤erence between
generics and brand-names, and these incentives are also stronger the larger the copayment
di¤erence between brand-names and generics. These e¤ects are empirically conrmed in the
second part of our paper, where we use Norwegian data on sales and prices at both producer
(ex-manufacturer) and retail (pharmacy) level for 70 o¤-patent substances with generic compe-
tition over a four-year period (2004-7). Controlling for retail price di¤erences of brand-names
and generics, we nd strong and highly signicant e¤ects of the di¤erence in brand-name and
generic margins on their market shares, implying that pharmacies are expending more e¤ort on
promoting generics when their margins on generics are high relative to those on brand-names.
Thus, our results strongly suggest that dispensing pharmacies are not perfect agents for patients
and that pharmacy incentives are important for stimulating generic sales.
Before concluding the paper, we would like to stress some potential caveats with our study.
Our theoretical analysis takes producer prices as given. Obviously, this is a simplifying assump-
tion. Producer prices are determined in negotiations between the (brand-name and generic)
producers and the wholesalers. It would be of great interest to study the determination of the
producer prices as a result of a bargaining game between these two parties, but this is clearly
beyond the scope of the paper and is therefore left for future research.
In our empirical study, we observe gross product margins. However, distribution costs might
di¤er across wholesalers and pharmacy chains, and give rise to di¤erent net margins. Moreover,
we do not observe potential side-payments between the producers and the wholesalers, which
might a¤ect the overall protability of selling specic products. However, as long as these factors
are fairly consistent over time, they should be captured by our substance-wholesaler xed e¤ects.
There are also regulations that restricts the use of side-payments. The government requires that
discounts given to the wholesalers should be reected in the producer prices and cannot be given
as a xed lump-sum transfer. It is also the case that the distributorsincentives are a¤ected by
the marginal protability of selling a specic product, which is exactly what we nd in our data.
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Appendix: Detailed descriptive statistics
A complete list of the set of substances in our sample, with descriptive statistics on key variables,
are given in Table A1.
[ Table A.1 about here ]
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Tables 
 
Table 1. Pharmacy chains, number of pharmacies, 2009. 
Alliance apotekene 144 
Apotek 1 244 
Vitusapotek 169 
Ditt Apotek (hospital pharmacies) 81 (33) 
Independent pharmacies 24 
Total 662 
 
 
 
Table 2. Sample characteristics, means and standard errors in parentheses.  
 Wholesaler 1 
Mean (SD) 
Wholesaler 2 
Mean (SD) 
Wholesaler 3 
Mean (SD) 
Industry 
      Mean (SD)        Min        Max 
Brand-name market 
share 
34.11 (27.03) 45.14 (29.64) 45.55 (31.85) 41.86 (30.11) 0.02 99.98 
Brand-name 
producer price1 
7.56 (19.90) 8.36 (18.80) 8.36 (19.22) 8.11 (19.29) 0.12 170.85 
Generic producer 
price1 
2.67 (4.77) 2.76 (4.00) 2.96 (4.62) 2.80 (4.47) 0.06 63.65 
Brand-name retail 
price1 
12.40 (29.01) 13.82 (27.91) 14.06 (28.57) 13.46 (28.49) 0.47 246.11 
Generic retail price1 9.97 (23.20) 11.79 (24.41) 11.19 (21.21) 11.01 (22.97) 0.42 235.79 
Brand name margin 4.84 (9.54) 5.46 (9.49) 5.70 (9.78) 5.35 (9.61) 0.01 86.67 
Generic margin 7.30 (19.84) 9.03 (22.03) 8.23 (18.40) 8.22 (20.15) 0.02 203.73 
Margin difference 2.46 (11.64) 3.57 (13.89) 2.53 (9.89) 2.86 (11.92) -28.01 154.12 
Number of 
observations 
 
4733 
 
5210 
 
5322 
 
15265 
  
1 Prices per DDD in Norwegian kroner (NOK).  
 
 
Table 3. The effect of pharmacy margins on brand-name market shares, fixed effect 
results with robust standard errors. 
 (1) (2) 
Producer price difference 0.489***  
(0.038) 
0.579*** 
 (0.037) 
Producer price difference* Ref. 
pricing 
 0.789*** 
 (0.036) 
Pharmacy price difference -0.773*** 
 (0.037) 
-0.464***  
(0.039) 
Reference pricing -3.700*** 
 (0.589) 
0.287 
(0.608) 
Wholesaler fixed effects Yes Yes 
Substance fixed effects Yes Yes 
Period fixed effects Yes Yes 
R2 0.210 0.234 
Number ATC-groups 70 70 
Number observations 15265 15265 
 *: p<0.10, **: p<0.05, ***: p<0.01 
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Table 4. The effect of pharmacy margins on brand-name market shares: Testing for 
asymmetric effects. 
  
Producer price difference 0.470*** 
 (0.044) 
Producer price difference* Brand-name 
margin >  Generic margin 
 
-0.159*** 
 (0.041) 
Brand-name margin >  Generic margin 2.848***  
(0.353) 
Pharmacy price difference -1.151***  
(0.044) 
Reference pricing -2.812*** 
(0.457) 
Constant 60.411***  
(0.871) 
Wholesaler fixed effects Yes 
Substance fixed effects Yes 
Period fixed effects Yes 
R2 0.255 
Number ATC-groups 72 
Number observations 15265 
*: p<0.10, **: p<0.05, ***: p<0.01 
 
 
 
Table 5. The effect of pharmacy margins on brand-name market shares, IV fixed 
effect results with robust standard errors (fixed effect: atc) 
 (1)a (2)b (3)c 
Producer price difference 0.487*** 
(0.039) 
0.383*** 
(0.138) 
0.338*** 
(0.133) 
Pharmacy price difference -0.731*** 
(0.039) 
-1.125*** 
(0.349) 
-1.218*** 
(0.282) 
Reference pricing -3.679*** 
(0.616) 
-3.209* 
(1.645) 
-1.763 
(1.646) 
Wholesaler fixed effects Yes Yes Yes 
Substance fixed effects Yes Yes Yes 
Period fixed effects Yes Yes Yes 
Overidentification test (Hansen J 
statistics) 
- - 0.917 
Underidentification test P-value - 0.000 0.000 
Weak identification test 
(Kleinberger-Paap rk Wald F statistics) 
- 14.684 12.189 
Number ATC-groups 58 58 58 
Number observations 13328 13328 12747 
*: p<0.10, **: p<0.05, ***: p<0.01 
a Same model as Model 1, Table 3, using the subsample for which we have Danish prices. 
b In Model 2 we use the pharmacy price difference in Denmark as instrument for the pharmacy price 
difference. 
c In Model 3 we use the pharmacy price difference in Denmark in t and t-1 as instrument for the 
pharmacy price difference. 
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Table A.1. Descriptive statistics (prices per DDD) 
ATC code Market  
share 
Margin 
difference 
Margin 
brand name 
Margin 
generics 
Pharmacy 
price brand 
name 
Pharmacy  
price  
generics 
Number 
substitution 
groups 
Ref. 
pricing 
Prices 
Danish 
data 
Number  
of obs. 
A02BA02 51.25 0.33 2.23 2.56 4.19 4.19 4 1.1.2005 Yes 575  
A02BA03 42.39 3.57 3.60 7.18 10.81 9.83 2 No No 286  
A02BC01 59.58 1.20 4.15 5.35 11.17 9.67 2 1.1.2005 Yes 246  
A02BC03 7.78 1.96 4.34 6.31 12.11 10.20 2 1.8.2005 No 26 
A03FA01 1.79 1.32 3.74 5.06 5.92 7.10 2 No No 181 
A04AA01 71.78 102.52 63.67 166.19 211.94 180.07 2 No   Yes 163 
A10BA02 63.25 0.43 1.11 1.54 2.19 2.20 3 No Yes 358 
A10BB12 61.87 0.48 0.89 1.37 1.83 1.64 4 1.10.2006 Yes 241 
C01DA14 34.68 0.58 1.18 1.76 2.64 2.50 1 No Yes 144 
C03DA01 13.99 0.44 1.32 1.76 3.14 2.86 3 No Yes 432 
C03EA01 26.31 -0.01 0.43 0.42 0.81 0.59 1 No Yes 141 
C07AA05 21.07 0.05 1.68 1.73 2.72 2.45 1 No Yes 13 
C07AB02 51.54 -2.40 4.65 2.25 6.67 3.47 5 No Yes 160 
C07AB03 27.25 0.28 0.82 1.10 1.56 1.52 3 1.1.2005 Yes 432 
C08CA01 22.35 0.14 1.32 1.46 3.33 1.86 2 1.1.2004 Yes 274 
C08CA02 25.59 0.65 0.95 1.60 2.34 1.93 2 1.1.2005 Yes 238 
C08DA01 29.34 0.37 1.59 1.96 3.02 2.79 3 No Yes 432 
C09AA02 36.27 0.24 1.49 1.73 2.45 2.34 4 1.1.2004 Yes 561 
C09AA03 33.28 0.55 1.41 1.96 3.04 2.84 4 1.1.2004 Yes 575 
C09AA05 50.57 0.46 1.02 1.47 1.97 1.92 4 1.1.2005 Yes 425 
C09BA02 37.95 0.76 1.62 2.37 3.48 3.37 1 1.1.2005 Yes 144 
C09BA03 27.04 0.61 1.74 2.35 4.16 3.07 2 1.1.2005 Yes 262 
C10AA01 23.81 0.57 1.15 1.72 2.50 2.40 4 1.5.2004 Yes 540 
C10AA02 33.47 3.24 4.30 7.53 11.20 9.63 2 No Yes 288 
C10AA03 16.20 0.36 2.03 2.39 6.99 3.28 2 1.1.2005 Yes 219 
D01BA02 10.07 4.17 6.32 10.50 20.25 12.66 1 1.8.2005 Yes 95 
G03CA03 25.02 0.19 0.89 1.07 2.47 2.86 2 No Yes 17 
G03HB01 51.02 0.55 0.87 1.42 2.17 1.79 1 No Yes 68 
H01BA02 80.70 -3.59 13.00 9.41 19.76 19.82 1 No Yes 49 
J01AA02 7.52 1.08 3.63 4.71 7.26 6.85 1 No No 68 
J01CA04 29.98 0.35 5.83 6.17 12.75 9.82 4 1.5.2005 Yes 457 
J01FA01 38.43 0.04 7.12 7.16 12.97 12.94 2 No Yes 280 
J01MA02 25.96 3.42 13.61 17.03 28.79 21.79 3 1.1.2005 Yes 266 
J02AC01 31.12 16.93 38.44 55.37 105.15 70.29 4 1.5.2005 Yes 428 
L02AE02 83.88 -0.23 13.52 13.28 48.02 48.02 3 No No 13 
L02BA01 44.41 1.12 2.00 3.12 5.21 4.49 2 No No 238 
L02BB03 76.13 18.67 14.41 33.07 49.71 43.18 2 No No 26 
L04AX03 86.61 -0.25 1.18 0.94 2.04 1.88 1 No No 138 
M01AB05 57.25 -0.41 2.80 2.39 4.46 3.68 2 1.1.2005 Yes 226 
M01AC01 8.51 0.78 1.67 2.45 3.51 3.37 1 No Yes 142 
M01AC06 82.86 0.21 3.22 3.44 4.58 5.07 2 1.12.2005 Yes 103 
M01AE01 4.08 0.57 2.20 2.77 3.72 3.79 3 No Yes 319 
M01AE02 10.10 0.39 1.40 1.79 2.91 2.74 2 No Yes 150 
M04AA01 35.65 0.46 1.63 2.09 2.80 2.75 2 No Yes 286 
M05BA04 13.21 1.15 2.96 4.11 10.26 4.93 2 1.12.2005 Yes 150 
N02AB03 82.07 10.99 14.64 25.63 40.40 36.18 5 No Yes 223 
N02AX02 37.68 1.01 8.67 9.68 12.45 11.68 1 No Yes 144 
N02BE01 29.61 0.53 1.60 2.12 2.35 2.91 2 No Yes 282 
N02CC01 69.09 4.58 15.26 19.85 38.51 32.22 2 1.6.2006 Yes 88 
N03AF01 87.62 0.09 3.61 3.70 6.88 6.44 2 No Yes 286 
N03AG01 96.84 0.05 6.33 6.39 14.86 12.70 1 No Yes 111 
N03AX09 95.94 14.43 13.66 28.09 38.13 32.95 4 No Yes 250 
N03AX11 93.14 9.98 16.36 26.34 48.02 41.49 4 No No 144 
N03AX12 85.38 6.67 15.50 22.17 35.41 32.07 3 No Yes 292 
N05AH02 37.34 4.92 7.84 12.76 21.10 19.41 2 No Yes 286 
N05AX08 27.49 0.05 10.65 10.70 31.48 20.24 4 Yes Yes 141 
N05BA01 27.40 0.20 2.41 2.61 3.41 3.25 1 No Yes 144 
N05BA12 90.73 -0.12 1.87 1.75 3.15 2.61 2 No Yes 36 
N05CD02 25.60 0.30 0.97 1.27 1.27 1.52 1 No Yes 144 
N05CF02 65.03 1.37 3.16 4.53 5.37 5.81 2 No Yes 288 
N06AB03 40.26 1.38 2.09 3.45 6.13 5.59 1 1.5.2005 Yes 144 
N06AB04 19.61 -0.51 3.06 2.54 7.99 4.18 2 1.1.2004 Yes 288 
N06AB05 27.62 0.48 2.45 2.92 5.61 4.24 1 1.1.2005 Yes 134 
N06AB06 56.04 1.29 2.25 3.54 5.95 4.88 2 1.5.2005 Yes 85 
N06AX03 88.60 0.14 2.70 2.84 4.95 5.82 3 1.3.2005 Yes 355 
N06AX11 69.57 0.25 4.25 4.50 7.35 7.14 2 1.1.2005 Yes 139 
N06BA04 99.87 2.41 3.39 5.80 7.07 9.15 1 No Yes 45 
R05CB01 40.85 0.10 2.45 2.55 4.22 4.23 1 No No 144 
R06AE07 23.92 -0.25 1.38 1.13 2.48 1.63 1 1.1.2004 No 143 
R06AX13 39.16 0.18 1.26 1.44 3.03 2.64 1 1.1.2004 No 54 
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We study the impact of product margins on pharmacies’ incentive to promote 
generics instead of brand-names. First, we construct a theoretical model where 
pharmacies can persuade patients with a brand-name prescription to purchase a 
generic version instead. We show that pharmacies’ substitution incentives are 
determined by relative margins and relative patient copayments. Second, we 
exploit a unique product level panel data set, which contains information on sales 
and prices at both producer and retail level. In the empirical analysis, we find a 
strong relationship between the margins of brand-names and generics and their 
market shares. This relationship is stronger for pharmaceuticals under reference 
pricing rather than coinsurance. In terms of policy implications, our results suggest 
that pharmacy incentives are crucial for promoting generic sales.
